# Nurix Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Nurix Therapeutics, Inc.). ## Overview Nurix Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing targeted protein degradation medicines. Its pipeline includes wholly owned and partnered drug candidates for cancer and inflammatory diseases, built around its DEL-AI discovery engine and ligase expertise. ## Products & services • Bexobrutideg (NX-5948) BTK degrader • Zelebrudomide (NX-2127) dual BTK/IKZF degrader • NX-1607 CBL-B inhibitor • Partnered IRAK4 degrader program (NX-0479/GS-6791) • Preclinical STAT6 degrader program • Degrader antibody conjugates (DACs) and discovery collaborations - **Wholly owned clinical-stage drug candidates** (0%) — Internal pipeline assets in clinical development for oncology and inflammatory disease. - **Partnered discovery and development programs** (100%) — Programs advanced with pharmaceutical partners under collaboration and license agreements. - **Preclinical degrader platform programs** (0%) — Earlier-stage degrader and DAC programs generated from the DEL-AI discovery engine. - Bexobrutideg (NX-5948) BTK degrader - Zelebrudomide (NX-2127) dual BTK/IKZF degrader - NX-1607 CBL-B inhibitor - Partnered IRAK4 degrader program (NX-0479/GS-6791) - Preclinical STAT6 degrader program - Degrader antibody conjugates (DACs) and discovery collaborations ## Customers Nurix’s direct counterparties are pharmaceutical partners that license, fund, or co-develop degrader programs, including Gilead, Sanofi, and Pfizer. If approved, its medicines would be sold to healthcare systems, insurers, and other payors serving patients with cancer or inflammatory diseases. - **Pharmaceutical collaboration partners** (primary) — Large pharma companies that license targets or co-develop degrader programs under collaboration agreements. - **Healthcare payors and reimbursement bodies** (primary) — Government and private payors that would reimburse approved products and influence uptake. - **Oncology and immunology treatment providers** (secondary) — Hospitals, clinics, and specialists that would prescribe or administer approved therapies. - **Patients with cancer and inflammatory disease** (primary) — The ultimate users of Nurix’s drug candidates if they are approved and commercialized. - Pharma partners that fund and co-develop discovery programs - Licensing counterparties for upfront, milestone, and extension payments - Hospitals and oncology centers if candidates reach commercialization - Payers and health systems that determine reimbursement access - Patients with cancer or inflammatory diseases as end users ## Geography Nurix is headquartered in Brisbane, California and operates as a U.S.-based biotechnology company. Its collaborations and trademark footprint extend internationally, with reported trademark registrations in Canada, Europe, Japan, Mexico, the United Kingdom, and the United States. Commercial exposure would be global if any candidates are approved, but current operations are centered in the United States. - Headquartered in Brisbane, California, United States - Core research and corporate operations are U.S.-based - Trademark registrations span North America, Europe, and Japan - Collaborations create exposure to global pharma markets - Future commercialization would depend on U.S. and ex-U.S. approvals ## Strategy Nurix’s strategy is to advance its lead degrader programs through clinical development while expanding the DEL-AI platform into additional targets and degrader modalities. It also uses collaborations to share development risk, generate non-product revenue, and preserve optionality for co-development or U.S. profit sharing on selected assets. - **Advance lead clinical programs** (short-term) — Clinical proof-of-concept is the main value driver for a pre-commercial biotech. - **Grow partnered discovery revenue** (medium-term) — Collaborations can offset R&D spend and validate the platform with major pharma partners. - **Expand the protein degradation platform** (long-term) — A broader target base increases the chance of finding differentiated drug candidates. - Advance bexobrutideg, zelebrudomide, and NX-1607 through clinical trials - Expand the DEL-AI platform to new targets and degrader classes - Use collaborations to fund development and broaden pipeline reach - Retain U.S. co-development and profit-sharing options where possible - Build IP, manufacturing, and regulatory capabilities for eventual launch ## Risks Nurix faces the typical risks of a clinical-stage biotech: clinical failure, regulatory setbacks, manufacturing scale-up issues, and dependence on external funding before product sales begin. Its platform also competes in a crowded field of protein degradation and other advanced therapeutic modalities, where larger companies may have more resources and faster development capabilities. - **Clinical development failure** [high] — Drug candidates may not demonstrate sufficient safety or efficacy in trials. - **Regulatory delay or refusal** [high] — FDA or other agencies may require more data, impose holds, or reject filings. - **Manufacturing and supply chain disruption** [high] — Early-stage third-party manufacturing can face scale-up, quality, or contamination issues. - **Financing dependence** [high] — The company has no approved products and must fund long development timelines. - **Competitive pressure** [medium] — Other protein degradation, antibody, gene therapy, and small-molecule programs may reach market first. - Clinical trials may fail to show safety or efficacy - FDA or other regulators may delay or refuse approvals - Manufacturing scale-up and cGMP compliance may disrupt supply - Additional capital will likely be needed before product sales - Competition is intense in protein degradation and oncology ## Accounting Nurix’s reported revenue is driven by collaboration and license arrangements, so revenue recognition depends on contract terms, performance obligations, and the timing of milestone or extension payments. As a pre-commercial biotech, it also relies heavily on management estimates for R&D accruals, stock-based compensation, and valuation allowances against deferred tax assets. - **Revenue recognition for collaborations and licenses** — Can cause uneven quarterly revenue - **R&D accrual estimates** — Affects operating expense and period comparability - **Stock-based compensation** — Raises reported operating expenses without cash outflow - **Deferred tax asset valuation allowance** — Limits recognition of tax benefits on the balance sheet - Collaboration and license revenue depends on contract milestones and obligations - Revenue timing can fluctuate with upfront and extension payments - R&D expense accruals depend on estimates for CRO and manufacturing work - Stock-based compensation affects operating expense and loss presentation - Full valuation allowance reflects uncertainty over future taxable income --- *Last updated: 2026-04-29T04:42:08.453291+00:00*